Trailhead Biosystems

About Trailhead Biosystems

Trailhead Biosystems, Inc. operates at the intersection of biotechnology and data science, focusing on regenerative medicine and drug discovery. Founded in 2015 by Dr. Jan Jensen and Michael Gilkey, the company emerged as a spinout from the Cleveland Clinic and Case Western Reserve University. Dr. Jensen, a molecular developmental biologist and bioinformatician, established the company based on his extensive research, particularly his work while holding an endowed professorship at the Cleveland Clinic. His scientific journey began in his home country of Denmark, where a free education system opened doors for him to pursue a Ph.D. at the University of Copenhagen, a path that eventually led him to a focus on curing diabetes.

The core of Trailhead's business is its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform. This technology combines advanced mathematical modeling, machine learning, and high-throughput robotic manufacturing to direct the differentiation of human induced pluripotent stem cells (iPSCs). In essence, the platform determines the optimal conditions needed to transform these stem cells into specific, functional human cell types with high precision and scalability. This process addresses a significant challenge in the field: recreating the complex cellular states essential for proper organ function outside the human body. By understanding the critical process parameters, the company can ensure the production of robust and stable cells for various applications.

Trailhead's business model serves two primary functions: providing highly specialized human cell models for research and supporting therapeutic partners. The company offers a portfolio of off-the-shelf iPSC-derived cells, such as dopaminergic neurons for Parkinson's research and vascular leptomeningeal cells for blood-brain barrier studies. It also provides custom cell differentiation services, allowing scientists to develop novel cell types for specific research needs. This capability is increasingly relevant as regulatory bodies like the FDA encourage human-based lab models as alternatives to animal testing. For therapeutic development, the company operates on a partnering model, providing what it terms "Active Cellular Ingredients" (ACIs) as clinical candidates for cell-based therapies. The company generates revenue through these products and services, targeting clients in drug discovery and regenerative medicine. Since its inception, Trailhead has secured significant funding, including a $20 million Series B round in May 2025, to expand its manufacturing capabilities, personnel, and strategic partnerships.